• Adaptilens

  Participated · Series A · Apr 2024

  Adaptilens is a Boston, MA-based pre-clinical biotech focused on advancing the standard of care for cataract surgery. Its core product, the Adaptilens A-IOL, is a soft, flexible, biomimetic accommodating intraocular lens that responds to the eye's natural signal to focus and aims to eliminate the need for eyeglasses or contact lenses. The company intends to use the new funding to drive development of the A-IOL through first-in-human trials. Adaptilens is led by founder and CEO Liane Clamen. The company raised $17.5M in a Series A round led by Perceptive Xontogeny Venture Funds, with participation from Pillar VC, 380 Cap, and Accanto Partners. As a pre-clinical company, its near-term milestones are clinical development steps rather than commercial deployment. Adaptilens is a Boston, MA-based company developing an accommodating intraocular lens (AdaptilensTM) that mimics the natural human lens. Led by Founder and CEO Dr. Liane Clamen, the device aims to give patients excellent near, intermediate, and distance vision without eyeglasses or contact lenses. The lens will initially be used for patients with cataracts. Adaptilens could also be used to correct a variety of refractive errors, including presbyopia. The company raised $1.6M in seed funding to support development of the accommodating intraocular lens. The round was led by Pillar VC with participation from Accanto Partners.

• Grouport

  Participated · Seed · Sep 2021

  Grouport operates a tech-enabled platform that delivers virtual, group-based treatment for chronic psychological disorders, with patients meeting weekly with the same members and therapist. The company was founded in 2019 by Jonathan Spievack (CEO) and Mordechai Teitz (co-founder and CTO) and is based in New York City. Its core product is an evidence-based, virtual group therapy model tailored to a range of mental health challenges. Grouport plans to scale its platform nationwide and grow its leadership team across marketing, technology, product, and business development. The company intends to use recent funding to support that expansion and to scale its tech and clinical operations. No operating metrics (revenue/users) were disclosed in the article.

No current team members are available.